WO2002043654A3 - Pharmaceutical composition and method for treatment of brain injury, spinal cord injury, stroke, neurodegenerative disease and other conditions - Google Patents

Pharmaceutical composition and method for treatment of brain injury, spinal cord injury, stroke, neurodegenerative disease and other conditions Download PDF

Info

Publication number
WO2002043654A3
WO2002043654A3 PCT/SE2001/002656 SE0102656W WO0243654A3 WO 2002043654 A3 WO2002043654 A3 WO 2002043654A3 SE 0102656 W SE0102656 W SE 0102656W WO 0243654 A3 WO0243654 A3 WO 0243654A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
pharmaceutical composition
stroke
conditions
spinal cord
Prior art date
Application number
PCT/SE2001/002656
Other languages
French (fr)
Other versions
WO2002043654A8 (en
WO2002043654A2 (en
Inventor
Milos Pekny
Original Assignee
Milos Pekny
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Milos Pekny filed Critical Milos Pekny
Priority to AU2002223170A priority Critical patent/AU2002223170A1/en
Publication of WO2002043654A2 publication Critical patent/WO2002043654A2/en
Publication of WO2002043654A3 publication Critical patent/WO2002043654A3/en
Publication of WO2002043654A8 publication Critical patent/WO2002043654A8/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2285—Endothelin, vasoactive intestinal contractor [VIC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Abstract

Disclosed is a pharmaceutical composition comprising a substance that upon administration to a patient leads to an inhibition of extension of cellular processes of astrocytes and/or a retraction of said cellular processes. Disclosed is also use of said substance for the production of a pharmaceutical composition for treatment of a condition selected from the group consisting of brain injury, spinal cord injury, stroke, neurodegenerative diseases, neuronal and/or synaptic loss associated with ageing, disorders of the brain associated with ageing and diabetic retinopathy, and also a method for treatment of said conditions wherein said substance is administered to a patient. Examples of such substances are quercetin, endothelin, hyaluronectin, L2 antibody, L2 glycolipid, L2 tetrasaccharide, TGF-alpha, or a tyrosine phosphatase inhibitor such as orthovanadate or phenylarsine oxide.
PCT/SE2001/002656 2000-12-01 2001-11-30 Pharmaceutical composition and method for treatment of brain injury, spinal cord injury, stroke, neurodegenerative disease and other conditions WO2002043654A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002223170A AU2002223170A1 (en) 2000-12-01 2001-11-30 Pharmaceutical composition and method for treatment of brain injury, spinal cord injury, stroke, neurodegenerative disease and other conditions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0004455-2 2000-12-01
SE0004455A SE0004455D0 (en) 2000-12-01 2000-12-01 Method of neuronal regeneration in the central nervous system

Publications (3)

Publication Number Publication Date
WO2002043654A2 WO2002043654A2 (en) 2002-06-06
WO2002043654A3 true WO2002043654A3 (en) 2002-09-06
WO2002043654A8 WO2002043654A8 (en) 2004-04-01

Family

ID=20282072

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE2001/002656 WO2002043654A2 (en) 2000-12-01 2001-11-30 Pharmaceutical composition and method for treatment of brain injury, spinal cord injury, stroke, neurodegenerative disease and other conditions

Country Status (3)

Country Link
AU (1) AU2002223170A1 (en)
SE (1) SE0004455D0 (en)
WO (1) WO2002043654A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5498571B2 (en) 2009-04-30 2014-05-21 ミッドウェスタン ユニバーシティ A novel treatment method using a centerkin
JP6928450B2 (en) * 2013-07-08 2021-09-01 ミッドウェスタン ユニバーシティ Compositions and Methods for Treating Neuropsychiatric Disorders Using Endothelin B Receptor Agonists
US20150190377A1 (en) * 2014-01-06 2015-07-09 The Regents Of The University Of California, A California Corporation Neuronal regeneration
WO2016172952A1 (en) 2015-04-30 2016-11-03 江苏挪贝肽医药科技有限公司 Application of pi4kiiiα protein and related membrane protein complex in treating alzheimer's disease

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998009523A1 (en) * 1996-09-05 1998-03-12 Massachusetts Institute Of Technology Compositions and methods for treatment of neurological disorders and neurodegenerative diseases
WO1998029547A1 (en) * 1996-12-31 1998-07-09 The Rockefeller University Modulators of radial glia-astrocyte differentiation and transformation, and diagnostic and therapeutic uses thereof
WO1999026621A1 (en) * 1997-11-24 1999-06-03 Bayer Aktiengesellschaft Application of substituted aminomethyl chromans in order to prevent neural degeneration and to promote neural regeneration

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998009523A1 (en) * 1996-09-05 1998-03-12 Massachusetts Institute Of Technology Compositions and methods for treatment of neurological disorders and neurodegenerative diseases
WO1998029547A1 (en) * 1996-12-31 1998-07-09 The Rockefeller University Modulators of radial glia-astrocyte differentiation and transformation, and diagnostic and therapeutic uses thereof
WO1999026621A1 (en) * 1997-11-24 1999-06-03 Bayer Aktiengesellschaft Application of substituted aminomethyl chromans in order to prevent neural degeneration and to promote neural regeneration

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
BIUNG YI WU ET AL.: "Quercetin inhibits c-fos, heat shock protein and glial fibrillary acidic protein expression in injured astrocytes", JOURNAL OF NEUROSCIENCE RESEARCH, vol. 62, 2000, pages 730 - 736, XP002909990 *
JAYA PADMANABHAN ET AL.: "Process formation in atrocytes: Modulation of cytoskeletal proteins", NEUROCHEMICAL RESEARCH, vol. 23, no. 3, 1998, pages 377 - 384, XP002909988 *
KOYAMA Y. ET AL.: "Endothelins are extracellular signals modulating cytoskeletal actin organization in rat cultured astrocytes", NEUROSCIENCE, vol. 61, no. 4, 1994, pages 1007 - 1016, XP002909989 *
KUENEMUND VOLKER ET AL.: "The LK2/HNK-1 carbohydrate of neutral cell adhesion molecules is involved in cell interactions", THE JOURNAL OF CELL BIOLOGY, vol. 106, January 1988 (1988-01-01), pages 213 - 223 *
MILOS PEKNY ET AL.: "Abnormal reaction to central nervous system injury in mice lacking glial fibrillary acidic protein and vimentin", THE JOURNAL OF CELL BIOLOGY, vol. 145, 1999, pages 503 - 514 *
NAMBOODIRI M.S. ARYAN ET AL.: "Hyaluronectin binds to laminin and blocks laminin-dependent process formation by astrocytes", NEUROREPORT, vol. 6, 1995, pages 2037 - 2040 *
RIXIN ZHOU ET AL.: "TGF-alpha differential regulates GFAP, vimentin and nestin gene expression in U-373 MG glioblastoma cells: correlation with cell shape and motility", EXPERIMENTAL CELL RESEARCH, vol. 254, 2000, pages 269 - 278 *
SADATH SULTANA ET AL.: "Effects of growth factors and basement membrane proteins of phenotypes of U-373 MG glioblastoma cells as determined by the expression of intermediate filament proteins", AMERICAN JOURNAL OF PATHOLOGY, vol. 153, no. 4, October 1998 (1998-10-01), pages 1157 - 1168 *
TASUKU SASAKI ET AL.: "Both cell-surface carbohydrates and protein tyrosine phosphatase are involved in the differentiation of astrocytes in vitro", GLIA, vol. 32, 2000, pages 60 - 70 *

Also Published As

Publication number Publication date
SE0004455D0 (en) 2000-12-01
WO2002043654A8 (en) 2004-04-01
WO2002043654A2 (en) 2002-06-06
AU2002223170A1 (en) 2002-06-11

Similar Documents

Publication Publication Date Title
WO2005115421A8 (en) Use of a compound comprising d-mannoheptulose and/or perseitol for treating and preventing innate immunity modification diseases
WO2003075921A3 (en) Mono- and bicyclic azole derivatives that inhibit the interaction of ligands with rage
CA2379695A1 (en) Compounds for modulating the rage receptor
BR0308196A (en) Compound, pharmaceutical formulation, use of a compound, methods for preventing and / or treating conditions associated with glycogen synthase kinase-3, and disease, and process for preparing a compound
BR0112589A (en) Heteroaryl derivatives and their application as a medicine
KR960700742A (en) ATOPIC DISEASE REMEDY
ATE373018T1 (en) ESTER DERIVATIVES OF HYALURONIC ACID FOR PRODUCING HYDROGEL MATERIALS BY PHOTOHARDENING
DE50102490D1 (en) USE OF SUBSTITUTED IMIDAZO [1,2-A] PYRIDINE, PYRIMIDINE AND PYRAZINE-3-YL-AMINE DERIVATIVES FOR PRODUCING MEDICINES FOR NOS INHIBITION
ATE329596T1 (en) PHTHALAZINE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES
WO2008060515A3 (en) Topical compositions comprising polyhydroxy acids and/or lactones for improved cutaneous effects of oxidative therapeutic drugs
BR0307291A (en) Compound; process for the preparation of a compound; pharmaceutical composition; use of a compound; method for the treatment and prophylaxis of various disorders and obesity in a human
AT506095A1 (en) USE OF PROTEASES
WO2002070473A3 (en) Carboxamide derivatives as therapeutic agents
ATE190840T1 (en) COMPOSITION FOR THE TREATMENT OF PARKINSON'S DISEASE
US11213560B2 (en) Method of promoting wound healing with sinetirucallol
Lewis et al. Inflammatory cytokines and peripheral mediators in the pathophysiology of pruritus in cutaneous T‐cell lymphoma
WO2022192594A3 (en) Nucleic acid molecules and vaccines comprising same for the prevention and treatment of coronavirus infections and disease
DE102011112496A1 (en) 4-methylcatechol derivatives and their use
WO2002043654A3 (en) Pharmaceutical composition and method for treatment of brain injury, spinal cord injury, stroke, neurodegenerative disease and other conditions
BR0116653A (en) Medicinal product containing a polyamine as active substance
ATE277625T1 (en) PHARMACEUTICAL COMPOSITION OF SPIDER VENOM AND THEREOF PRODUCTION AND USE FOR THE TREATMENT OF TUMOR DISEASES
ATE399015T1 (en) MEDICINAL PRODUCTS FOR THE RELIEF OF INTESTINAL DISEASES
ATE252383T1 (en) USE OF 2-METHYL-THIAZOLIDINE-2,4-DICARBONIC ACID AND/OR ITS PHYSIOLOGICALLY TOLERABLE SALTS FOR THE PRODUCTION OF A MEDICATION FOR THE TREATMENT OF CANCER DISEASES
WO2003103699A8 (en) Use of ramoplanin to treat diseases associated with the use of antibiotics
PT1231908E (en) PHARMACEUTICAL COMPOSITION UNDERSTANDING A NON-BREAKING COMPOUND AND ITS USE IN THERAPY

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ CZ DE DE DK DK DM DZ EC EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 23/2002 DUE TO A TECHNICAL PROBLEMAT THE TIME OF INTERNATIONAL PUBLICATION, SOME INFORMATION WAS MISSING UNDER (81). THE MISSING INFORMATION NOW APPEARS IN THE CORRECTED VERSION

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP